Diligence memo · auto-generated · as of July 2, 2026

Optima Neuroscience Inc

Optima Neuroscience Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Optima Neuroscience Inc operates in Biotechnology, based in ALACHUA.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Optima Neuroscience Inc has raised $1.2M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $593K on —.

Most recent recorded round closed around 2010-02-12.

Valuation (modeled)modeled

Provath models Optima Neuroscience Inc at approximately $15M (range $141K–$166M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.75× the median modeled value of Pre-Seed Biotechnology companies in 2010–2012 (132 peers) — value vs value, same stage and era. Within the normal band (75% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 241 months.

Last raise 16.4 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.2× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 20% of Biotechnology peers (4293 compared).

Modeled value ranks above 24% of those peers.

Closest niche peers: Hygeia Therapeutics, Inc., Act Biotech Inc, Ikonopedia, LLC, Iquum Inc, Koronis Pharma, Inc..

Peoplefiled

8 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.